Because HER2 expression levels are too low in sarcoma cells for a monoclonal antibody-based approach to be therapeutically actionable, HER2-positive sarcoma patients may be more sensitive to HER2-directed CAR T cell therapy (161). This evidence concerns the gene ERBB2 and sarcoma.